Drug therapy in prediabetes

Journal of the Indian Medical Association

Volumn 103, Issue 11, 2005, Pages 603-608

  Mukhopadhyay, Pradip ^a   Chowdhury, Subhankar ^a  

^a IPGME and R   (India)

Author keywords

Exercise; Prediabetes

Indexed keywords

ACARBOSE; ACARBOSE8; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; GLICLAZIDE; GLITAZONE DERIVATIVE; METFORMIN; NATEGLINIDE; PIOGLITAZONE; PLACEBO; RIMONABANT; ROSIGLITAZONE; TETRAHYDROLIPSTATIN; THIAZIDE DIURETIC AGENT; TROGLITAZONE; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; HUMAN; IMPAIRED FASTING GLUCOSE; IMPAIRED GLUCOSE TOLERANCE; LIVER TOXICITY; META ANALYSIS; REVIEW; SYSTEMATIC REVIEW; CARDIOVASCULAR DISEASE; DISEASE COURSE; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS;

ACARBOSE; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; METFORMIN; PREDIABETIC STATE; THIAZOLIDINEDIONES;

EID: 33646451996     PISSN: 00195847     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. American Diabetes Association - Prevention or delay of type 2 diabetes. Diabetes Care 2004; 27: S47-54.
2. Follow-up of long-term studies: Diabetes Prevention Project. Diabetic Retinopathy Occurs in Pre-Diabetes. Presented at 65th Scientific Session of American Diabetes Association, San Diego, California, June 2005.
3. Diabetes Prevention Research Group - Reduction in the evidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2004; 346: 393-403.
4. Wenying Y, Lixiang L, Jinwu Q, et al - The preventive effect of acarbose and metformin on the progression of diabetes mellitus in the IGT population: a 3-year multicentre prospective study. Chin J Endocrinol Metab 2001; 17: 131-5.
5. Chaisson JL, Josse RG, Gomis R, et al, - For the STOP NIDDM Trial Research Group: acarbose for prevention of type 2 diabetes mellitus; the STOP NIDDM randomised trial. Lancet 2002; 359: 2072-7.
6. Holman RR, North BV, Tunbridge FK - Possible prevention of type 2 diabetes mellitus with acarbose and metformin. Diabetes 2000; 49: 450-6.
7. Chaisson JL, Josse RG, Gomis R, et al - Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM Trial. JAMA 2003; 290: 486-94.
8. Hanefeld M, Chaisson JL, Koehler C - Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004; 35: 1073-8.
9. Buchanon TA, Xiang AT, Peters RK, et al - Preservation of pancreatic beta cell function of type 2 diabetes mellitus by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002; 51: 2796-803,
10. Durbin RJ - Thiozolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetologia 2002; 45: SA 105.
11. Mizushige K, Tsuji T, Noma T - Pioglitazone: cardiovascular effects in prediabetic patients. Cardiovasc Drug Reviews 2002; 20: 329-40.
12. The DREAM Trial Investigators - Rationale, design, and recruitment characteristics of a large international trial of diabetes prevention: The DREAM Trial. Diabetologia 2004; 47: 1519-27.
13. Saloranta C, Guitard C, Prcher E, et al - Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population. Diabetes Care 2002; 25: 2141-6.
14. The NAVIGATOR Trial Steering Committee - Nateglinide and valsartan in impaired glucose tolerance outcome research: rational and design of the NAVIGATOR trial (Abstract). Diabetes 2002; 51: A116.
15. Sartor G, Schersten B, Carlstorm S, et al - Ten-year follow-up of subjects with impaired glucose tolerance. Prevention of diabetes by tolbutamide and diet regulation. Diabetes 1980; 29: 41-9.
16. Dyson PA, Hammersley MS, Morris RJ, et al - The Fasting Hyperglycemia Study: II. Randomized control trial of reinforced healthy living advice in subjects with increased but not diabetic fasting glucose. Metabolism 1997; 46: S50-5.
17. Sjostorm L, Togerson JS, Hauptman J, et al - XENDOS (Xenical in the prevention of diabetes in obese subjects): a landmark study. The 9th International Congress on obesity, Sao Paulo, Brazil, 2002.
18. Hansson L, Lindholm LH, Niskanen L, et al - Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension. The Captopril Prevention Project Randomized Trial. Lancet 1999; 353: 611-6.
19. Dahlop B, Devereux RB, Kjeldsen SE, et al, for the LIFE study group - The cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction: a randomized trial against atenolol. Lancet 2002; 359: 995-1003.
20. Hansson L, Lindholm LH, Ekbom T, et al - Randomized trial of new and old antihypertensive drugs in elderly patients: cardiovascular morbidity and mortality in the Swedish trial in old patients with hypertension-2 study (STOP-2). Lancet 1999; 354: 1751-6.
21. Gillespie EL, White MC, Kardas M, Lindberg M, Coleman CI - The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 2005; 28: 2261-5.